In short
Clinical trials of Sacubitril Valsartan are studying how this treatment is used in heart failure care. The trials look at safety, effectiveness, quality of life, and treatment patterns in adults with heart failure, including women and patients with reduced ejection fraction.
Key points
- Clinical trials of Sacubitril Valsartan are focused on heart failure, including chronic heart failure with reduced ejection fraction. Both listed studies are Phase 3 and are authorized. One trial studies sex differences in heart failure treatment use and outcomes, while the other looks at whether blood drug levels are linked to better heart failure control. The target groups include adults with heart failure and women with heart failure. Main outcomes include death, hospital readmission, worsening heart failure, quality of life, adherence, and side effects.
Trial overview
Two authorized Phase 3 trials are studying Sacubitril Valsartan in people with heart failure. One trial is focused on a possible sex gap in heart failure treatment, meaning differences between women and men in how guideline-directed medical therapy is prescribed and used. The other trial studies whether blood drug levels are more useful than the dose itself for understanding heart failure control.
Who is being studied
The first study includes patients with heart failure and focuses especially on women in a prospective, pragmatic, multicentre trial. The second study includes patients with chronic heart failure with reduced ejection fraction, which means long-term heart failure where the heart pumps out less blood than normal. Together, these studies look at adults with heart failure in different clinical settings.
What the trials measure
The first trial measures all-cause mortality, heart failure readmission, and worsening heart failure within 1 year. It also studies quality of life, adherence to treatment, and side effects. The second trial measures whether serum concentrations of the listed medicines, including Sacubitril Valsartan, are linked to clinical indicators of heart failure.
How the trials are designed
The first study has both a retrospective part and a prospective part. The retrospective part reviews national registry and database data to describe current prescribing patterns and inequality related to sex. The prospective part compares up-titration of guideline-directed medical therapy, using the STRONG-HF titration programme, with usual care.
The second study is an interventional Phase 3 trial that compares several heart failure medicines, including beta-blockers, spironolactone, and Sacubitril Valsartan, by looking at their serum concentrations and clinical effects. Its goal is to see whether drug levels in the blood are more important than the prescribed dose for compensating health status.
What these studies may mean for patients
These trials are not testing Sacubitril Valsartan in isolation, but as part of broader heart failure care. They may help researchers understand whether treatment is being used fairly, whether treatment changes improve outcomes, and whether blood testing can help guide therapy better.
Because the studies focus on heart failure, the findings are most relevant for people living with this condition, especially women and patients with reduced ejection fraction.